title: Different influence of CGRP (8-37), an amylin and CGRP antagonist, on the anorectic effects of cholecystokinin and bombesin in diabetic and normal rats.
abstract: Because previous studies had suggested that the anorectic effects of cholecystokinin (CCK) and bombesin (BBS) depend partly on the release of amylin or calcitonin gene-related peptide (CGRP), we investigated the influence of the amylin and CGRP receptor antagonist CGRP (8-37) on the anorectic effects of CCK and BBS in streptozotocin (STZ)-diabetic and nondiabetic rats. STZ-diabetic rats had significantly lower plasma amylin and insulin concentrations than nondiabetic control rats. Amylin (5 micrograms/kg or 2.5 micrograms/rat) injected IP at dark onset after 24-h food deprivation elicited an anorectic effect of similar extent in STZ-diabetic and control rats. Under similar conditions, CCK (0.25 and 2 micrograms/kg) and BBS (5 micrograms/kg) reduced food intake in both STZ-diabetic and nondiabetic rats. These effects were markedly attenuated by CGRP (8-37) (10 micrograms/kg) in non-diabetics but not in STZ-diabetic rats. It is concluded that part of the anorectic effects of CCK and BBS depend on the release of amylin from pancreatic B-cells.
authors.affiliation: Institute of Veterinary Physiology, University of Zuerich, Switzerland.
authors.forename: T A
authors.initials: TA
authors.lastname: Lutz
authors.forename: T R
authors.initials: TR
authors.lastname: Pieber
authors.forename: B
authors.initials: B
authors.lastname: Walzer
authors.forename: E
authors.initials: E
authors.lastname: Del Prete
authors.forename: E
authors.initials: E
authors.lastname: Scharrer
mesh_terms: D000682:Amyloid / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D000818:Animals; D000855:Anorexia / Q000139:chemically induced* / Q000378:metabolism; D001839:Bombesin / Q000008:administration & dosage / Q000187:drug effects*; D015740:Calcitonin Gene-Related Peptide / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D002766:Cholecystokinin / Q000008:administration & dosage / Q000187:drug effects*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism; D004338:Drug Combinations; D004435:Eating; D007274:Injections, Intraperitoneal; D058228:Islet Amyloid Polypeptide; D008297:Male; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D013311:Streptozocin
chemical_list: D000682:Amyloid; D004338:Drug Combinations; D058228:Islet Amyloid Polypeptide; D010446:Peptide Fragments; C058636:calcitonin gene-related peptide (8-37); D013311:Streptozocin; D002766:Cholecystokinin; D015740:Calcitonin Gene-Related Peptide; D001839:Bombesin